CNR1 and Hepatic steatosis: For example, peripheral organ-specific CB1R inverse agonist and antagonist (i.e., JD5037 and AM6545) were developed to reduce neuropsychiatric side effects, which were successful in reducing and improving cardiometabolic risks and hepatic steatosis in animal experiments.34,46